Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Igor Krasulya
Igor Krasulya

DeepOriginBio partnership accelerates BioAge Labs progress on human aging drug discovery

DeepOriginBio partnership accelerates BioAge Labs progress on human aging drug discovery
BioAge Labs moves to hit-to-lead

BioAge Labs has moved a new target for human aging from initial data to promising chemical matter within a matter of months.

The company, collaborating with DeepOriginBio, has now validated the initial hits in the laboratory and is proceeding into the hit-to-lead optimization phase. BioAge Labs also signaled intent to expand its efforts in this research domain.

Earlier this year, BioAge Labs presented research indicating that oral NLRP3 inhibition may reverse age-related deficits in mice at a leading science meeting, according to company disclosures. The findings marked a step in BioAge's approach to addressing aging through molecular interventions. The new hit-to-lead program builds on this sequence of preclinical advances.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Solana vs. Base: Who will dominate the token launch market?
  • By Pavlo Kot
  • 20 hours ago
Solana vs. Base: Who will dominate the token launch market?
Editors' Picks
Jobs in crypto: Which specialists are in demand now?
  • By Pavlo Kot
  • Yesterday
Jobs in crypto: Which specialists are in demand now?
Editors' Picks
Poland's crypto paradox: A growing market caught in regulatory deadlock
  • By Anastasiia Chabaniuk
  • 16.10.2026
Poland's crypto paradox: A growing market caught in regulatory deadlock
Editors' Picks
All Editors' Top Picks

Latest BioAge Labs News

BioAge Labs presents oral NLRP3 inhibition research on reversing aging effects in mice
  • By Mykhailo Ihnatenko
  • 28.09.2026
BioAge Labs presents oral NLRP3 inhibition research on reversing aging effects in mice
Companies
#BioAge Labs
Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research
  • By Andreas Kristo
  • 30.07.2026
Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research
Companies
#BioAge Labs
BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment
  • By Ivan Andriyenko
  • 10.07.2026
BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment
Companies
#BioAge Labs
All BioAge Labs News
  • Pavlo Kot
  • 20 hours ago
Solana vs. Base: Who will dominate the token launch market?
  • Pavlo Kot
  • Yesterday
Jobs in crypto: Which specialists are in demand now?
  • Anastasiia Chabaniuk
  • 16.10.2026
Poland's crypto paradox: A growing market caught in regulatory deadlock
  • Eugene Komchuk
  • 16.10.2026
Jimmy Song: Trump has failed to meet Bitcoiners' expectations
  • Dmytro Kharkov
  • 16.10.2026
Cash is trash: Inflation forces savers to invest or lose purchasing power
  • Daria Chernytska
  • 27 min ago
Spiros Margaris: AI could make investing tools accessible but not guarantee better decisions
  • Yaroslav Dmytrenko
  • 47 min ago
MA breaks prior record near $600, Danny Naz notes
  • Hanna Syniavska
  • 52 min ago
Federal Reserve meeting could influence $84,000 target, Anndy Lian notes
  • Pavlo Kot
  • 1 hour ago
Shares details of trading decisions and outcomes, Roy Bhasin notes
  • Oksana Koneva
  • 1 hour ago
Trading becomes complex when neckline violations are meaningless, Peter Brandt notes
Top News
  • Kyle Torpey
  • 16 hours ago
Venezuela targets $76B oil investment as production recovery accelerates
Venezuela targets $76B oil investment as production recovery accelerates
  • Mykhailo Ihnatenko
  • 17 hours ago
Crypto selloff deepens as institutional outflows meet heavy liquidations
Crypto selloff deepens as institutional outflows meet heavy liquidations
  • Ashutosh Sureka
  • 18 hours ago
US AI data center boom hits financing and construction roadblocks
US AI data center boom hits financing and construction roadblocks
  • Pavlo Kot
  • 20 hours ago
Solana vs. Base: Who will dominate the token launch market?
Solana vs. Base: Who will dominate the token launch market?
  • Ciaran Ryan
  • Yesterday
Oil trader who made billions for Vitol departs amid losses
Oil trader who made billions for Vitol departs amid losses
Live News
  • Eugene Komchuk
  • Now
Circle plans to expand USDC into 40 new markets
  • Hanna Syniavska
  • Now
Shell plans to sell French mobility assets to DCC Energ
  • Anton Kharitonov
  • Now
EUR/USD holds above 1.1260 as falling U.S. yields overshadow sticky inflation
  • Mykhailo Ihnatenko
  • Now
Tesla stock climbs over 4% after high-profile Roadster presentation
  • Parshwa Turakhiya
  • Now
Tether invests in Saber Money to strengthen stablecoin payment networks
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers